Mp60-14 Survival Patterns Based on Site-Specific Visceral Metastasis in Metastatic Prostate Cancer Patients: Are Outcomes of Visceral Metastases the Same?

You have accessJournal of UrologyProstate Cancer: Advanced (Including Drug Therapy) III (MP60)1 May 2024MP60-14 SURVIVAL PATTERNS BASED ON SITE-SPECIFIC VISCERAL METASTASIS IN METASTATIC PROSTATE CANCER PATIENTS: ARE OUTCOMES OF VISCERAL METASTASES THE SAME? Mohamed E. Ahmed, Wael O. Zeina, Ahmed Mahmoud, Daniel S. Childs, A. Tuba Kendi, Matthew K. Tollefson, R. J. Karnes, Eugene D. Kwon, and Jack R. Andrews Mohamed E. AhmedMohamed E. Ahmed , Wael O. ZeinaWael O. Zeina , Ahmed MahmoudAhmed Mahmoud , Daniel S. ChildsDaniel S. Childs , A. Tuba KendiA. Tuba Kendi , Matthew K. TollefsonMatthew K. Tollefson , R. J. KarnesR. J. Karnes , Eugene D. KwonEugene D. Kwon , and Jack R. AndrewsJack R. Andrews View All Author Informationhttps://doi.org/10.1097/01.JU.0001008804.84010.ec.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Metastatic visceral involvement in prostate cancer patients conveys a poor prognosis. Survival patterns of site-specific visceral metastasis are poorly understood. Herein, we sought to investigate survival patterns in prostate cancer patients according to their first detected site of visceral metastasis. METHODS: Retrospectively, we identified 200 patients with visceral metastatic prostate cancer. Patients were divided into three groups according to first-site detected visceral metastases. Visceral metastases were detected on either conventional imaging (CT/MRI), metabolic imaging (C-11 choline), or PSMA PET-CT scan. Follow up duration was 5 years. RESULTS: Table 1 demonstrates clinical and pathological variables of study groups. Patients with first-site lung metastases have significant better survival outcomes compared to patients with first-site brain or liver metastases (p<0.0001) (Figure 1A). In subset analysis of patients with CRPC, Figure 1B demonstrates the K-M curve of overall survival, which demonstrates better survival outcomes in patients with first-site lung metastases in comparison with patients with first-site brain or liver metastases (p<0.0001). CONCLUSIONS: Our data suggests that prostate cancer patients with visceral metastatic disease have different survival patterns according to first-site detected visceral metastasis. In our cohort, patients with first-site lung metastasis demonstrated better survival outcomes than patients with first-site brain or liver metastasis. Further studies are warranted. Download PPT Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1005 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Mohamed E. Ahmed More articles by this author Wael O. Zeina More articles by this author Ahmed Mahmoud More articles by this author Daniel S. Childs More articles by this author A. Tuba Kendi More articles by this author Matthew K. Tollefson More articles by this author R. J. Karnes More articles by this author Eugene D. Kwon More articles by this author Jack R. Andrews More articles by this author Expand All Advertisement PDF downloadLoading ...